Monday, October 11, 2021 3:18:18 PM
There is absolutely no truth to this at all
“Dead money”
“Dead money”
Recent SRPT News
- Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference • Business Wire • 05/13/2026 08:30:00 PM
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/13/2026 08:22:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:10:17 PM
- Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments • Business Wire • 05/06/2026 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:01:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 08:11:01 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 08:10:20 PM
- Sarepta Therapeutics to Announce First Quarter 2026 Financial Results • Business Wire • 04/22/2026 12:30:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • InvestorsHub NewsWire • 04/20/2026 01:00:00 PM
- When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/31/2026 08:05:00 PM
- Sarepta shares jump after early clinical data from siRNA programs • IH Market News • 03/25/2026 03:31:46 PM
- Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 • Business Wire • 03/25/2026 12:05:00 PM
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 • Business Wire • 03/24/2026 08:05:00 PM
- Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® • Business Wire • 03/19/2026 12:30:00 PM
- Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne • Business Wire • 03/16/2026 12:33:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:09:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:05:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:03:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:01:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 12:08:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/12/2026 12:07:03 AM
